omni bio pharmaceutical inc (OMBP) Key Developments
Omni Bio Pharmaceutical, Inc. Receives Notice of Allowance for the Use of Alpha-1 Antitrypsin to Reduce Risk of Non-Organ Transplant Rejection and to Treat Graft Versus Host Disease
Nov 26 13
Omni Bio Pharmaceutical, Inc. announced that it has received a notice of allowance from the Canadian Patent Office for the use of AAT in reducing the risk of a non-organ transplant rejection, reducing the risk of developing graft versus host disease (GvHD) and for treating GvHD in patients who have received a cornea, bone marrow, stem cell or pancreatic islet cell transplant. Patent applications covering similar claims are under review in the U.S. and Europe. The claims granted by this notice of allowance include a composition comprising AAT or a carboxyterminal peptide corresponding to AAT or combination thereof, and a carrier or diluent, for use in: reducing a non-organ transplant rejection or for reducing the risk of a non-organ transplant rejection, wherein the non-organ transplant is selected from the group consisting of cornea, bone marrow, stem cell, pancreatic islet, and a combination thereof; and reducing the risk of developing symptoms of GvHD, or for treating GvHD in a subject that has received a non-organ transplant, wherein the non-organ transplant is selected from the group consisting of cornea, bone marrow, stem cell, pancreatic islet, and a combination thereof.
Omni Bio Pharmaceutical, Inc. Announces Reduction in Inflammatory Myocardial Injury with its Lead Recombinant Molecule
Nov 20 13
Omni Bio Pharmaceutical, Inc. announced important results from new studies of its recombinant molecule, Fc-AAT. Reduced infarct size by nearly 50% relative to each control agent; almost fully prevented reduction of Left Ventricular Ejection Fraction (LVEF), a measure of cardiac contractility; was comparable to the effects of plasma-derived AAT but did so with a 40 times lower dose; and was comparable to another recombinant Fc-AAT construct that had been engineered not to have neutrophil elastase inhibitory activity. The study concluded that recombinant Fc-AAT reduces inflammatory myocardial injury following ischemia-reperfusion in the mouse leading to preservation of viable myocardium and systolic function independent of its elastase inhibitory function. AAT is the most abundant circulating serine protease inhibitor in the body and an acute phase reactant. Systemic deficiency in AAT due to genetic mutations can result in debilitating liver failure and chronic lung disease such as emphysema. Lifelong treatment with plasma-derived AAT, intravenously administered, is indicated for such patients. Recent evidence suggests that AAT plays an important role in modulating immunity, inflammation and apoptosis. AAT protects various cell types from cell death, inhibits caspases-1 and -3 activity and has been shown to be effective in a wide variety of animal models of human disease, including diabetes, graft versus host disease (rejection reactions following bone marrow or other transplantation procedures), refractory gout, myocardial infarction and inflammatory bowel disease.
Omni Bio Pharmaceutical, Inc. Receives Notice of Allowance for its First U.S. Patent Action for Recombinant Alpha-1 Antitrypsin Molecule
Nov 6 13
Omni Bio Pharmaceutical, Inc. announced that it has received a Notice of Allowance for its first U.S. patent for the composition of matter of its lead recombinant molecule, Fc-AAT. The claims contained in this Notice of Allowance cover full-length AAT nucleic acid constructs that encode polypeptide components of Omni Bio's Fc-AAT recombinant fusion molecule as well as other AAT fusion polypeptides. Similar patent applications covering Omni Bio's lead Fc-AAT molecule remain under review in Europe and Canada. Patent applications for a series of follow-on Fc-AAT constructs are also pending on a worldwide basis.
Omni Bio Pharmaceutical, Inc. Announces Board Changes
Aug 15 13
On August 9, 2013, Vicki Barone and Steven Bathgate announced their intentions to resign as members of the board of directors of Omni Bio Pharmaceutical, Inc., effective August 14, 2013. Ms. Barone was serving as the Chairperson of the board and as a member of the Audit Committee. Both Ms. Barone and Mr. Bathgate are resigning for personal reasons and are not resigning because of a disagreement with the company or on any matter relating to its operations, policies or practices. Effective August 13, 2013, Bruce Schneider, the company's CEO, was appointed as the Chairman of the company's board of directors.
Omni Bio Pharmaceutical, Inc. Appoints Sandra J. Wrobel to its Board of Directors
Jul 17 13
Omni Bio Pharmaceutical, Inc. announced the appointment of Ms. Sandra J. Wrobel, to its Board of Directors, effective July 15, 2013. Ms. Wrobel is currently CEO and Managing Director, Applied Strategies Consulting, LLC. She previously served as CFO and Vice President Business Operations at Intrabiotics Pharmaceuticals, Inc. and held a series of positions over twelve years at Strategic Decisions Group, culminating in Managing Director of their Life Sciences Consulting Practice.